Journal
AMERICAN HEART JOURNAL
Volume 164, Issue 3, Pages 334-U239Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2012.06.005
Keywords
-
Categories
Funding
- AstraZeneca
- Eli Lilly/Daiichi Sankyo
- Merck
- Eli Lilly
- Bristol-Myers Squibb
- Johnson Johnson
- Bayer
- Regado Biosciences
- Daiichi-Sankyo
- Eisai
- Lilly
- Sanofi-Aventis
- GlaxoSmithKline
- Pfizer
- Servier
- Portola
- The Medicines Company
- Schering-Plough
- Daiichi Sankyo
- EliLilly/Daiichi-Sankyo
- Accumetrics
- Medscape
- Abbott
- Boehringer Ingelheim
- Menamni
- Novartis
- Bristol-Myers Squibb/Pfizer
- Portola Pharmaceutical
Ask authors/readers for more resources
Background Habitual smoking has been associated with increased platelet reactivity, increased risk of thrombotic complications and greater efficacy of clopidogrel therapy over placebo. In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) reduced the primary composite end point of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding. We evaluated the results in relation to smoking habits. Methods Interactions between habitual smokers (n = 6678) and in ex/nonsmokers (n = 11,932) and the effects of randomized treatments on ischemic and bleeding outcomes were evaluated by Cox regression analyses. Results Habitual smokers had an overall lower risk profile and more often ST-elevation ACS. After adjustment for baseline imbalances, habitual smoking was associated with a higher incidence of definite stent thrombosis (adjusted HR, 1.44 [95% CI, 1.07-1.94]); there were no significant associations with other ischemic or bleeding end points. The effects of ticagrelor compared to clopidogrel were consistent for all outcomes regardless of smoking status. Thus, there was a similar reduction in the primary composite end point for habitual smokers (adjusted HR, 0.83 [95% CI, 0.68-1.00]) and ex/nonsmokers (adjusted HR, 0.89 [95% CI, 0.79-1.00]) (interaction P = .50), and in definite stent thrombosis for habitual smokers (adjusted HR, 0.59 [0.39-0.91]) and ex/nonsmokers (adjusted HR, 0.69 [95% CI, 0.45-1.07]) (interaction P = .61). Conclusions In patients hospitalized with ACS, habitual smoking is associated with a greater risk of subsequent stent thrombosis. The reduction of vascular death, myocardial infarction, stroke, and stent thrombosis by ticagrelor compared to clopidogrel is consistent regardless of smoking habits. (Am Heart J 2012;164:334-342.e1.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available